Medicine News and Research

RSS

AACR to host special conference on colorectal cancer

The American Association for Cancer Research will hosts its first special conference on Colorectal Cancer: Biology to Therapy from Oct. 27-30, 2010, at the Loews Hotel, Philadelphia.

22 Oct 2010

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon Inc., a life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new, traceable DNA delivery platform created to deliver genetic medicine to cells while carrying a beacon so scientists can follow its progress.

22 Oct 2010

Patients are under-informed about treatments; Home-based care gains popularity

A survey of more than 3,000 patients age 40 and older reveals that physicians often leave information out when they present treatment plans to patients, who "hear far more from doctors about the pros than cons of medications, tests and surgeries." Often, "physicians tend to offer opinions, not options, the researchers found, and rarely mention to patients that they can decide not to do anything," according to the study, which was funded by the Foundation for Informed Medical Decision Making.

22 Oct 2010

Scientists discover new cell that may limit inflammation in CNS

Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.

22 Oct 2010

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in forced expiratory volume in one second (FEV1, a measure of lung function) percent predicted across three treatment cycles (six months).

22 Oct 2010

American Academy takes measures to attract women to become orthopaedic surgeons

Only 3.9 percent of orthopaedic surgeons and 13.8 percent of orthopaedic residents are women, according to the American Academy of Orthopaedic Surgeons. The academy is working to attract more women to the specialty by placing advertisements in medical student publications and sponsoring booths at medical student meetings.

22 Oct 2010

Mount Sinai School of Medicine launches inner-city mental health program for children

Research has shown that nearly 40 percent of youth in low-income communities exhibit significant mental health needs - needs which remain largely unaddressed due to a myriad of barriers, including system-level obstacles, such as waiting lists, stigma related to seeking mental health care, poverty, family stress and competing priorities.

22 Oct 2010

Drug payment database spurs local reports

A database put together by ProPublica of drugmakers' payments to physicians for promoting their products is now spurring local inquiries and garnering some response from physicians.

22 Oct 2010

Stanford Hospital opens Nuclear Medicine and Molecular Imaging Clinic

The Nuclear Medicine and Molecular Imaging Clinic opening this month at Stanford Hospital will help advance a new generation of diagnostic techniques for earlier detection and improved management of cancer, heart disease and neurological disorders.

22 Oct 2010

Researchers suggest gene therapy may treat patients with major depression

In a report published in the Oct. 20 issue of Science Translational Medicine, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center say animal and human data suggest gene therapy to the brain may be able to treat patients with major depression who do not respond to traditional drug treatment.

22 Oct 2010

Parent-only treatments for childhood obesity work effectively: Researchers

A study led by a researcher at the University of California, San Diego School of Medicine indicates that parent-only treatments for childhood obesity work equally as well as plans that include parents and child, while at the same time more cost effective and potentially easier for families. The results were published today in the advanced online edition of the journal Obesity.

22 Oct 2010

NIH awards three new SBIR grants to Taiga

Taiga Biotechnologies, Inc. today announced that the company has received three new Small Business Innovation Research (SBIR) grants from the National Institutes of Health, totaling $1.7 million. This adds to the two previous grants awarded to Taiga for various applications of its proprietary technology platforms, for a total in NIH funding to date of over $2.1 million.

22 Oct 2010

Research determine 3D structure of egg receptor molecule that binds sperm

Researchers at the Swedish medical university Karolinska Institutet have been able to describe the 3D structure of a complete egg receptor that binds sperm at the beginning of fertilization. The results, published in the journal Cell, will lead to better understanding of infertility and may enable entirely new types of contraceptives.

22 Oct 2010

UCLA researchers receive NIH grant to study HIV-positive men from LA County jails

A team of UCLA researchers has received a $4.6 million grant from the National Institutes of Health to study ways to get HIV-positive men who have been released from Los Angeles County jails into medical care and on sustained treatment.

22 Oct 2010

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Regulus Therapeutics Inc. announced today that advancements from its leading microRNA platform and product pipeline were presented at the "6th Annual Meeting of the Oligonucleotide Therapeutics Society" held October 20 - 23, 2010 in Dana Point, California.

22 Oct 2010

Clinical research scholar receives grant to promote lifestyle changes for HIV patients

Between the demands of work, family and friends, many women find health takes a back seat. Women with HIV are no exception. "Many women with the HIV face challenges from sleepless nights to little personal time-all activities that can negatively impact health," says Allison Webel, a clinical research scholar and instructor at the Frances Payne Bolton School of Nursing at Case Western Reserve University.

22 Oct 2010

Pinch of salt: How much is enough?

Salt restriction in the normal diet has come under debate. While scientists are questioning the complex role of sodium in the body and the need for salt restriction, surveys have found that dietary sodium has not gone down well in large populations despite awareness on the risks of too much salt intake.

21 Oct 2010

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate compared with vancomycin for the primary endpoint. The ZEPHyR (Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to methicillin-resistant Staphylococcus aureus) study was the largest ever conducted in this population.

21 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

Kensey Nash 2011 first quarter decreases 14% to $17.0 million

Kensey Nash Corporation , a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2010.

21 Oct 2010